

MEDICARE FORM

Trelstar[®] (triptorelin pamoate) Medication Precertification Request

Page 1 of 2

(All fields must be completed and legible for precertification review.)

Virginia (HMO D-SNP) FAX: 1-833-280-5224 PHONE: 1-855-463-0933

For other lines of business: Please use other form

Note: Trelstar is non-preferred. The preferred product is Eligard. Firmagon is also a preferred product.

Please indicate:								
		• •	last treatment	/ / Dhana		Гом		
Precertification Req A. PATIENT INFORM				Priorie	e:	Fax:		
First Name:	MATION		Last Name:			DOB:		
Address:			Last Name.	City:		State:	ZIP:	
Home Phone:		Work Phone:		Cell Phone:		Email:	ZIF.	
	at: lbe or	I	nt Height:inches	l	Allergies:	Liliali.		
B. INSURANCE INFO		kgs Falleli	it Heightinches	citis	Allergies.			
Aetna Member ID #:			Does patient have oth	ner coverage?	☐ Yes ☐ No			
Group #:			If yes, provide ID#: Carrier Name:					
Insured:			Insured:					
Medicare: Yes	No If yes, provi	de ID #:	Me	edicaid: 🗌 Yes	☐ No If yes, prov	ide ID #:		
C. PRESCRIBER INF	ORMATION							
First Name:			Last Name:		(Check On	e):	D.O. N.P. P.A.	
Address:				City:		State:	ZIP:	
Phone:	Fax:		St Lic #:	NPI #:	DEA #:		UPIN:	
Provider Email:			Office Contact Name			Phone:		
Specialty (Check one	e): 🔲 Oncologist	☐ Endocrinol	logist 🗌 Other:					
D. DISPENSING PRO	OVIDER/ADMINIS	TRATION INFOR	RMATION					
Outpatient Infusion Center Name: Home Infusion Cen Agency Name Administration code Address: City: Phone: TIN:	Center Ph	State: Z Fax:	IIP:	Name: Address: City: Phone: TIN:	y Pharmacy	State: Fax: PIN:	ZIP:	
E. PRODUCT INFOR	MATION							
Request is for: Trels		•		Freque				
F. DIAGNOSIS INFO	RMATION - Pleas	e indicate primar	y ICD code and specif					
Primary ICD Code:			Secondary ICD Cod	•		CD Code:		
			ation must be complete	d in its <u>entirety</u> fo	or all precertification	requests.		
Preservation of ov Yes No Is Prostate cancer Note: Trelstar is non- Yes No Has th	the requested med Yes No Is the No Will Yes No Will Please indicate the Trarian function The patient premen Preferred. The preserved a trial	ication being presone patient undergone the patient received anner Stage of pulpopausal and undergonder is and failure, intole	cribed for pubertal supplying gender reassignmente the requested medical berty the patient has reastragoing chemotherapy? Eligard. Firmagon is a prance, or contraindication the patient cannot use Eligard.	nt? ion concomitantly ched: Stage I stage I stage I stage I to stage I t	with gender affirming Stage II ☐ Stage II oroduct.	I] Stage V □ Unknown	
·	·						_	



MEDICARE FORM

Trelstar[®] (triptorelin pamoate) Medication Precertification Request

Page 2 of 2

(All fields must be completed and legible for precertification review.)

Virginia (HMO D-SNP) FAX: 1-833-280-5224 PHONE: 1-855-463-0933

For other lines of business:

Please use other form

Note: Trelstar is non-preferred. The preferred product is Eligard. Firmagon is also a preferred product.

Patient First Name	Patient Last Name	Patient Phone	Patient DOB
G. CLINICAL INFORMATION (conti	n ued) – Required clinical inform	ation must be completed in its entirety	for all precertification requests.
For Continuation Requests (clinical	documentation required for a	II requests):	
☐ Gender dysphoria			
☐ Yes ☐ No Is the requested i	medication being prescribed for	pubertal suppression in an adolescent	patient?
└────────────────────────────────────	Is the patient undergoing gende	r transition?	
☐ Yes ☐ No	Will the patient receive the requ	ested medication concomitantly with ge	ender affirming hormones?
Please indicate t	he Tanner Stage of puberty the p	oatient has reached: 🗌 Stage I 🔲 Stage	e II 🗌 Stage III 🗌 Stage IV 🔲 Stage V 🗌 Unknov
☐ Preservation of ovarian function			
☐ Yes ☐ No Is the patient pre	menopausal and still undergoing	chemotherapy?	
☐ Prostate cancer			
☐ Yes ☐ No Has the patient h	ad prior therapy with Trelstar wit	thin the last 365 days?	
☐ Yes ☐ No Has the patient e	xperienced clinical benefit to the	rapy while receiving the requested drug	g (e.g., serum testosterone less than 50 ng/dl)?
☐ Yes ☐ No Has the patient exper	ienced an unacceptable toxicity	while receiving the requested drug?	
H. ACKNOWLEDGEMENT			
Request Completed By (Signature	e Required):		Date: / /
	g materially false information	or conceals material information for	rvice with the intent to injure, defraud or deceing the purpose of misleading, commits a fraudule

The plan may request additional information or clarification, if needed, to evaluate request.